ADCT logo

ADCT
Adc Therapeutics SA

1,258
Mkt Cap
$431.18M
Volume
648,500.00
52W High
$4.98
52W Low
$2.25
PE Ratio
-3.21
ADCT Fundamentals
Price
$3.39
Prev Close
$3.40
Open
$3.41
50D MA
$3.79
Beta
1.55
Avg. Volume
933,511.33
EPS (Annual)
-$1.12
P/B
-1.99
Rev/Employee
$421,538.86
$626.76
Loading...
Loading...
News
all
press releases
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada
Royal Bank Of Canada reiterated an 'outperform' rating and issued a $6.00 price target on shares of ADC Therapeutics in a research note on Tuesday...
News Placeholder
More News
News Placeholder
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
News Placeholder
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
read more...
News Placeholder
ADC Therapeutics Q1 Earnings Call Highlights
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. ZYNLONTA revenue rises to $20 million as c...
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -10.53% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
ADC Therapeutics (NYSE:ADCT) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
ADC Therapeutics (NYSE:ADCT - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06. The firm had revenue of $20.85 million during the quarter, compared to analysts...
News Placeholder
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates PR...
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
News Placeholder
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, May 1, 2026 LAUSANNE...
News Placeholder
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday
ADC Therapeutics (NYSE:ADCT) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-adc-therapeutics-sa-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available